迪瑞医疗(300396) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥182,424,018.64, a decrease of 72.47% compared to ¥662,535,125.59 in the same period last year[5] - Net profit attributable to shareholders was ¥15,678,683.66, down 87.13% from ¥121,800,597.55 year-on-year[5] - Total operating revenue for the current period was ¥182,424,018.64, a significant decrease of 72.5% compared to ¥662,535,125.59 in the previous period[22] - Net profit for the current period was ¥15,677,203.80, a decrease of 87.1% compared to ¥121,793,477.11 in the previous period[23] - Basic and diluted earnings per share for the current period were both ¥0.0575, down from ¥0.4466 in the previous period[23] Cash Flow - The net cash flow from operating activities improved by 77.33%, reaching -¥41,723,517.67, compared to -¥184,049,664.39 in the previous year[5] - The net cash flow from operating activities was -41,723,517.67, an improvement from -184,049,664.39 in the previous period, indicating a reduction in cash outflow[25] - Cash inflow from operating activities totaled 208,512,287.80, down 27.2% from 286,322,068.49 in the prior period[25] - Cash outflow from operating activities decreased to 250,235,805.47 from 470,371,732.88, reflecting a 46.8% reduction[25] - The net cash flow from investing activities decreased by 116.94%, primarily due to the lack of new financial product purchases[13] - The net cash flow from investing activities was -2,795,904.72, compared to a positive cash flow of 16,503,423.86 in the previous period[25] - Cash inflow from investing activities was only 220.00, significantly lower than 174,288,796.33 in the prior period[25] - Cash outflow from investing activities decreased to 2,796,124.72 from 157,785,372.47, a reduction of 98.2%[25] - The net cash flow from financing activities was -153,126,702.55, worsening from -2,835,595.10 in the previous period[26] - Cash inflow from financing activities was 45,000,000.00, slightly down from 45,151,555.82 in the prior period[26] - Cash outflow from financing activities increased to 198,126,702.55 from 47,987,150.92, a rise of 313.5%[26] - The ending cash and cash equivalents balance was 389,760,256.23, down from 670,694,518.02 in the previous period[26] Assets and Liabilities - The total assets decreased by 6.83% to ¥2,895,358,808.01 from ¥3,107,533,388.27 at the end of the previous year[5] - Total current assets decreased from 1,844,110,841.82 yuan to 1,635,127,222.60 yuan, a decline of approximately 11.3%[19] - Cash and cash equivalents decreased from 586,680,294.87 yuan to 393,260,256.23 yuan, a decline of approximately 33.1%[19] - Total liabilities decreased to ¥825,581,940.55 from ¥1,058,764,060.35, a reduction of 22.0%[21] - The total equity attributable to shareholders of the parent company increased to ¥2,069,765,611.38 from ¥2,048,756,770.93, an increase of 1.0%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,877[15] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 28.34% of shares, totaling 77,288,400 shares, with 45,600,156 shares pledged[15] - Guangdong Hengjian International Investment Co., Ltd. holds 12.15% of shares, totaling 33,123,600 shares[15] Operational Strategy - The company installed over 400 high-speed instruments in the domestic market during the first quarter, indicating a focus on increasing reagent sales[8] - The company adjusted its sales strategy in international markets, particularly focusing on Southeast Asia and Belt and Road Initiative countries[8] - The company plans to enhance operational efficiency by implementing cost-cutting measures and increasing reagent sales[8] Research and Development - Research and development expenses decreased by 34.09% to ¥2,100,000.00, due to optimized project spending[10] - Research and development expenses for the current period were ¥21,117,372.39, a decrease of 34.1% from ¥32,040,993.06 in the previous period[22] - The company has not disclosed any new product or technology developments in the current reporting period[18] Inventory and Receivables - Accounts receivable increased slightly from 441,690,051.18 yuan to 441,722,093.25 yuan[19] - Inventory decreased from 576,420,879.57 yuan to 559,041,927.84 yuan, a decline of approximately 3.0%[19] - Long-term equity investments increased from 450,858,277.53 yuan to 454,373,373.16 yuan[19] Other Financial Metrics - Operating costs decreased by 75.23% to ¥104,000,000.00, reflecting the reduction in revenue[10] - Total operating costs for the current period were ¥174,838,646.92, down 67.1% from ¥532,151,957.58 in the previous period[22] - The company reported a financial expense of -¥7,407,661.00, compared to a financial expense of ¥1,246,558.73 in the previous period, indicating a significant improvement[22] - Other comprehensive income after tax for the current period was ¥5,330,335.74, compared to ¥542,085.22 in the previous period, showing a substantial increase[23]